J Feenstra

982 total citations
19 papers, 613 citations indexed

About

J Feenstra is a scholar working on Pediatrics, Perinatology and Child Health, Pharmacology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, J Feenstra has authored 19 papers receiving a total of 613 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pediatrics, Perinatology and Child Health, 3 papers in Pharmacology and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in J Feenstra's work include Atrial Fibrillation Management and Outcomes (2 papers), Pituitary Gland Disorders and Treatments (2 papers) and Child Abuse and Related Trauma (2 papers). J Feenstra is often cited by papers focused on Atrial Fibrillation Management and Outcomes (2 papers), Pituitary Gland Disorders and Treatments (2 papers) and Child Abuse and Related Trauma (2 papers). J Feenstra collaborates with scholars based in Netherlands and Myanmar. J Feenstra's co-authors include Bruno H. Stricker, Diederick E. Grobbee, Eibert R. Heerdink, WW de Herder, J. A. M. J. L. Janssen, AJ van der Lely, RA Feelders, Paul D. van der Linden, Eugène van Puijenbroek and Bas A. in't Veld and has published in prestigious journals such as The Lancet, Heart and British Journal of Clinical Pharmacology.

In The Last Decade

J Feenstra

18 papers receiving 584 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J Feenstra Netherlands 10 211 170 135 129 87 19 613
Fang Niu United States 14 147 0.7× 124 0.7× 126 0.9× 91 0.7× 35 0.4× 49 777
Stefano Buda Italy 14 158 0.7× 153 0.9× 46 0.3× 426 3.3× 45 0.5× 65 858
Cheryl P. Magno United States 5 136 0.6× 377 2.2× 51 0.4× 166 1.3× 36 0.4× 6 841
Christoph Pachler Austria 8 145 0.7× 78 0.5× 39 0.3× 81 0.6× 47 0.5× 15 591
Daniala L. Weir Canada 12 315 1.5× 104 0.6× 29 0.2× 210 1.6× 32 0.4× 31 714
Andrew Weekes Australia 11 216 1.0× 81 0.5× 98 0.7× 156 1.2× 23 0.3× 22 716
Jean‐Pierre Fauvel France 16 111 0.5× 118 0.7× 46 0.3× 289 2.2× 96 1.1× 68 883
Yung‐Chang Chen Taiwan 19 142 0.7× 121 0.7× 40 0.3× 144 1.1× 34 0.4× 52 984
Helen MacLaughlin Australia 17 95 0.5× 225 1.3× 35 0.3× 92 0.7× 44 0.5× 52 835
Barbara J. Zarowitz United States 13 38 0.2× 71 0.4× 80 0.6× 49 0.4× 52 0.6× 40 570

Countries citing papers authored by J Feenstra

Since Specialization
Citations

This map shows the geographic impact of J Feenstra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Feenstra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Feenstra more than expected).

Fields of papers citing papers by J Feenstra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J Feenstra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Feenstra. The network helps show where J Feenstra may publish in the future.

Co-authorship network of co-authors of J Feenstra

This figure shows the co-authorship network connecting the top 25 collaborators of J Feenstra. A scholar is included among the top collaborators of J Feenstra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J Feenstra. J Feenstra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Feenstra, J, Maarten O. van Aken, Wouter W. de Herder, Richard A. Feelders, & A. J. van der Lely. (2006). Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. European Journal of Endocrinology. 154(6). 805–806. 28 indexed citations
2.
Feenstra, J, et al.. (2005). Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. The Lancet. 365(9471). 1644–1646. 179 indexed citations
3.
Stoelhorst, Gerlinde M. S. J., Monique Rijken, Shirley E. Martens, et al.. (2003). Developmental outcome at 18 and 24 months of age in very preterm children: a cohort study from 1996 to 1997. Early Human Development. 72(2). 83–95. 74 indexed citations
4.
Feenstra, J, Eibert R. Heerdink, Diederick E. Grobbee, & Bruno H. Stricker. (2002). Association of Nonsteroidal Anti-inflammatory Drugs With First Occurrence of Heart Failure and With Relapsing Heart Failure. Archives of Internal Medicine. 162(3). 265–265. 124 indexed citations
5.
Linden, Paul D. van der, Eugène van Puijenbroek, J Feenstra, et al.. (2001). Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis & Rheumatism. 45(3). 235–239. 104 indexed citations
6.
Linden, Paul D. van der, Eugène van Puijenbroek, J Feenstra, et al.. (2001). Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis & Rheumatism. 45(3). 235–239. 10 indexed citations
7.
Bleumink, Gysèle S., J Feenstra, & Bruno H. Stricker. (2001). [Drug-induced heart failure].. PubMed. 145(25). 1200–3. 1 indexed citations
8.
Feenstra, J, et al.. (2000). Mesenteric Venous Thrombosis Attributed to Docetaxel. American Journal of Clinical Oncology. 23(4). 353–354. 9 indexed citations
9.
Feenstra, J, et al.. (1999). [The need for 'postmarketing surveillance'].. PubMed. 143(14). 711–3. 1 indexed citations
10.
Feenstra, J, Bas A. in't Veld, Paul D. van der Linden, Diederick E. Grobbee, & Bruno H. Stricker. (1998). Risk factors for mortality in users of ibopamine. British Journal of Clinical Pharmacology. 46(1). 71–77. 12 indexed citations
11.
Heeringa, Marten, et al.. (1998). [Major psychiatric side effects of interferon alpha-2b].. PubMed. 142(28). 1618–21. 8 indexed citations
12.
Feenstra, J, et al.. (1998). Prevention of relapse in patients with congestive heart failure: the role of precipitating factors. Heart. 80(5). 432–436. 37 indexed citations
13.
Puijenbroek, Eugène van, J Feenstra, & R.H.B. Meyboom. (1998). [Pill cycle disturbance in simultaneous use of itraconazole and oral contraceptives].. PubMed. 142(3). 146–9. 4 indexed citations
14.
Feenstra, J, et al.. (1998). [Acute myocardial infarct following sulprostone administration].. PubMed. 142(4). 192–5. 9 indexed citations
15.
Feenstra, J, et al.. (1997). Fever attributed to the use of hydroxyurea. The Netherlands Journal of Medicine. 51(3). 110–113. 2 indexed citations
16.
Feenstra, J & Bruno H. Stricker. (1996). [Heart failure and fluid retention attributed to the use of non-steroidal anti-inflammatory drugs].. PubMed. 140(40). 2000–3. 1 indexed citations
17.
Feenstra, J, et al.. (1996). [Methotrexate; fatal dosage errors due to inattention].. PubMed. 140(30). 1533–5. 1 indexed citations
18.
Koopman, Hendrik M. & J Feenstra. (1988). [Fraud in medicine with the child as victim. Munchausen syndrome by proxy. A review of the literature].. PubMed. 56(4). 141–8. 1 indexed citations
19.
Feenstra, J, et al.. (1988). [A case of Munchausen syndrome by proxy].. PubMed. 56(4). 148–53. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026